XSTO
ISOFOL
Market cap25mUSD
Jul 10, Last price
0.91SEK
1D
2.72%
1Q
-49.13%
IPO
-96.60%
Name
Isofol Medical AB (publ)
Chart & Performance
Profile
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 721 -94.37% | 12,797 -42.89% | ||||||||
Cost of revenue | 38,734 | 35,136 | 178,504 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (38,734) | (34,415) | (165,707) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (3,812) | |||||||||
Tax Rate | ||||||||||
NOPAT | (38,734) | (34,415) | (161,895) | |||||||
Net income | (43,488) 17.31% | (37,071) -76.23% | (155,943) -20.79% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 23 | |||||||||
BB yield | -0.02% | |||||||||
Debt | ||||||||||
Debt current | 1,543 | |||||||||
Long-term debt | 6,353 | |||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 648 | 911 | 846 | |||||||
Net debt | (96,157) | (138,148) | (182,737) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (41,986) | (52,536) | (190,975) | |||||||
CAPEX | ||||||||||
Cash from investing activities | 101 | |||||||||
Cash from financing activities | (1,681) | |||||||||
FCF | (38,731) | (30,404) | (164,163) | |||||||
Balance | ||||||||||
Cash | 96,157 | 138,148 | 190,583 | |||||||
Long term investments | 50 | |||||||||
Excess cash | 96,157 | 138,112 | 189,993 | |||||||
Stockholders' equity | (1,140,332) | (1,096,844) | (1,059,129) | |||||||
Invested Capital | 1,218,925 | 1,219,188 | 1,222,401 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 161,067 | 161,515 | 161,515 | |||||||
Price | 2.22 204.11% | 0.73 -1.35% | 0.74 -91.99% | |||||||
Market cap | 357,568 203.26% | 117,906 -1.35% | 119,521 -89.70% | |||||||
EV | 261,411 | (20,242) | (63,216) | |||||||
EBITDA | (38,734) | (34,378) | (164,065) | |||||||
EV/EBITDA | 0.59 | 0.39 | ||||||||
Interest | 44 | |||||||||
Interest/NOPBT |